Relacionar Columnas Diabetes Oral MedsVersión en línea NUr115 Oral Diabetic Agents por Concetta Fiorentino 1 Enhances glucose-dependent insulin secretion. 2 Stimulate pancreas to secrete insulin. 3 Sensitize body tissue to insulin: stimulates insulin receptor sites. 4 Drug to drug interaction with NSAIDS. 5 Do not increased insulin secretion. 6 Stimulate beta cells of the pancreas. 7 Usually given once a day. 8 Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels. 9 Prevents kidneys from reabsorbing glucose. 10 Possible side-effect of impaired platelet function. 11 Inhibit production of glucose by the liver. Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl) Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix) Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity) Januvia Avandia Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset) Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia) Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus) glipizide Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance)
Crear